TELA Bio
Life science company offering surgical reconstruction.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $40.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 62 % | 41 % | 41 % | 19 % | 23 % | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (139 %) | (101 %) | (94 %) | (70 %) | (57 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (158 %) | (113 %) | (107 %) | (80 %) | (55 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 23 % | 23 % | 22 % | 16 % | 13 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
TELA Bio, Inc. is a commercial-stage medical technology company that provides soft-tissue reconstruction solutions designed to preserve and restore a patient's anatomy. Incorporated in 2012 and headquartered in Malvern, Pennsylvania, the company was co-founded by Antony Koblish and Dr. Maarten Persenaire. Koblish, who serves as President and CEO, is a medical device entrepreneur with extensive experience in the healthcare sector, including his prior role as President and CEO of Orthovita, an orthobiologics and biosurgery company acquired by Stryker Corporation. His background in mechanical engineering and applied mechanics has informed the company's direction.
The company's business model centers on the sale of its proprietary products through a direct sales force, primarily in the United States. TELA Bio generates revenue from its portfolio of OviTex® and OviTex PRS® Reinforced Tissue Matrix products. These products are used in various surgical procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. In November 2019, TELA Bio held its initial public offering (IPO) on the Nasdaq Global Market under the ticker symbol "TELA", raising approximately $52.0 million.
The company's core product line, OviTex, is a reinforced biologic mesh made from layers of ovine (sheep) rumen interwoven with polymer sutures. This design aims to offer the benefits of both biologic and synthetic materials, providing strength while minimizing long-term foreign material exposure. The OviTex portfolio includes various configurations with permanent or resorbable polymers to suit different surgical needs and techniques, including open, laparoscopic, and robotic procedures. Recently, the company launched OviTex IHR, specifically designed for inguinal hernia repair. TELA Bio also markets LIQUIFIX™, an FDA-approved liquid adhesive for internal mesh fixation during hernia surgery.
Keywords: soft tissue reconstruction, medical devices, hernia repair, OviTex, surgical mesh, abdominal wall reconstruction, regenerative medicine, biosurgery, plastic surgery, tissue matrix